Back to results
US 2023/0069760 A1Published application
Anti-vtcn1 antibodies and antibody drug conjugates
AssigneeBluefin BioMedicine, Inc.
InventorsAilan Guo, Svetlana Popova, Scott Michael Lonning, Jason G. Beaudet
Life of this patent
Estimating the term…
Abstract
Disclosed herein are anti-V-set domain containing T cell activation inhibitor 1 (VTCN1) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
Claims18
-297. (canceled)
An anti-VTCN1 antibody, or antigen-binding portion thereof, comprising
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 239, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 238, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 237, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 227, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 226, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 225;
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 251, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 250, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 249, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 255, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 254, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 253;
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 267, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 266, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 265, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 271, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 270, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 269;
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 267, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 285, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 284, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 287, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 254, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 269;
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 267, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 280, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 279, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 282, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 254, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 269;
- or
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 215, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 214, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 213, and a light chain variable region comprising a CDR3 domain comprising the amino acid sequence of SEQ ID NO:
- 219, a CDR2 domain comprising the amino acid sequence of SEQ ID NO:
- 218, and a CDR1 domain comprising the amino acid sequence of SEQ ID NO:
- 217.
40 more elements
An anti-VTCN1 antibody, or antigen-binding portion thereof, comprising
- a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 236 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 224;
- a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 248 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 252;
- a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 264 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 268;
- a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 283 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 286;
- a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 278 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 281;
- or
- a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 212 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO:
- 216.
16 more elements
An anti-VTCN1 antibody, or antigen-binding portion thereof, comprising a heavy chain comprising an amino acid sequence set forth in SEQ ID NO:
- 236, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 236, and/or a light chain comprising an amino acid sequence set forth in SEQ ID NO:
- 224, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 224;
- a heavy chain comprising an amino acid sequence set forth in SEQ ID NO:
- 248, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 248, and/or a light chain comprising an amino acid sequence set forth in SEQ ID NO:
- 252, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 252;
- a heavy chain comprising an amino acid sequence set forth in SEQ ID NO:
- 264, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 264, and/or a light chain comprising an amino acid sequence set forth in SEQ ID NO:
- 268, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 268;
- a heavy chain comprising an amino acid sequence set forth in SEQ ID NO:
- 283, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 283, and/or a light chain comprising an amino acid sequence set forth in SEQ ID NO:
- 286, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 286;
- a heavy chain comprising an amino acid sequence set forth in SEQ ID NO:
- 278, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 278, and/or a light chain comprising an amino acid sequence set forth in SEQ ID NO:
- 281, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 281;
- or
- a heavy chain comprising an amino acid sequence set forth in SEQ ID NO:
- 212, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 212, and/or a light chain comprising an amino acid sequence set forth in SEQ ID NO:
- 216, or a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:
- 216.
27 more elements
Dependencies are inferred from the claim text.